busulfan has been researched along with Glial Cell Tumors in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 9.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| "The glutathione synthase inhibitor, buthionine sulfoximine (BSO), specifically enhances the cytotoxic effects of treosulfan in human glioma cells." | 7.71 | CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. ( Baumgart, J; Seyfried, J; Stock, J; Weller, M; Wick, W; Wüllner, U, 2002) |
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 5.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| "The glutathione synthase inhibitor, buthionine sulfoximine (BSO), specifically enhances the cytotoxic effects of treosulfan in human glioma cells." | 3.71 | CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. ( Baumgart, J; Seyfried, J; Stock, J; Weller, M; Wick, W; Wüllner, U, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Younis, IR | 1 |
| Elliott, M | 1 |
| Peer, CJ | 1 |
| Cooper, AJ | 1 |
| Pinto, JT | 1 |
| Konat, GW | 1 |
| Kraszpulski, M | 1 |
| Petros, WP | 2 |
| Callery, PS | 1 |
| ONESTI, P | 1 |
| WOODLIFF, HJ | 1 |
| Gururangan, S | 1 |
| Poussaint, TY | 1 |
| Hancock, ML | 1 |
| Phillips, PC | 1 |
| Friedman, HS | 2 |
| Bomgaars, L | 1 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Reber, U | 1 |
| Wüllner, U | 2 |
| Trepel, M | 1 |
| Baumgart, J | 2 |
| Seyfried, J | 2 |
| Klockgether, T | 1 |
| Dichgans, J | 1 |
| Weller, M | 2 |
| Coggins, CA | 1 |
| Elion, GB | 1 |
| Houghton, PJ | 1 |
| Hare, CB | 1 |
| Keir, S | 1 |
| Colvin, OM | 1 |
| Bigner, DD | 1 |
| Bouffet, E | 1 |
| Raquin, M | 1 |
| Doz, F | 1 |
| Gentet, JC | 1 |
| Rodary, C | 1 |
| Demeocq, F | 1 |
| Chastagner, P | 1 |
| Lutz, P | 1 |
| Hartmann, O | 1 |
| Kalifa, C | 1 |
| Wick, W | 1 |
| Stock, J | 1 |
| Mungyerová, G | 1 |
| Jacz, K | 1 |
| Kuzma, I | 1 |
| Babusiková, O | 1 |
| Kalafut, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis[NCT00006246] | Phase 1 | 28 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors[NCT02684071] | Phase 2 | 3 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Lack of additional funding; patients (3) no longer receiving intervention.) | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for busulfan and Glial Cell Tumors
| Article | Year |
|---|---|
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Experiences with malignant brain tumours in clinic and in tissue culture.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Arsenicals; Astrocytoma; Brain Neoplasms; Busulfan; Clin | 1965 |
6 other studies available for busulfan and Glial Cell Tumors
| Article | Year |
|---|---|
Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.
Topics: Alanine; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cell Line, Tumor; Glioma; Glutathione | 2008 |
EFFECT OF DRUGS ON CELLS IN VITRO.
Topics: Animals; Busulfan; Glioma; In Vitro Techniques; Leukemia; Leukemia, Experimental; Leukemia, Myeloid; | 1963 |
Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Buthionine Sulfoximine; Drug Synergism | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biops | 2000 |
CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Blood Cell C | 2002 |